-
1
-
-
84901445280
-
Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment
-
Halban PA, Polonsky KS, Bowden DW et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014; 37: 1751–1758.
-
(2014)
Diabetes Care
, vol.37
, pp. 1751-1758
-
-
Halban, P.A.1
Polonsky, K.S.2
Bowden, D.W.3
-
2
-
-
0028817815
-
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease
-
U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–1258.
-
(1995)
Diabetes
, vol.44
, pp. 1249-1258
-
-
-
3
-
-
84919999219
-
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
-
(2015)
Diabetes Care
, vol.38
, pp. 140-149
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
4
-
-
0032983666
-
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)
-
UK Prospective Diabetes Study (UKPDS) Group, Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–2012.
-
(1999)
JAMA
, vol.281
, pp. 2005-2012
-
-
Turner, R.C.1
Cull, C.A.2
Frighi, V.3
Holman, R.R.4
-
5
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
-
(2008)
N Engl J Med
, vol.359
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.5
-
6
-
-
84883423061
-
The future of basal insulin
-
Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther 2013; 15: 727–732.
-
(2013)
Diabetes Technol Ther
, vol.15
, pp. 727-732
-
-
Shah, V.N.1
Moser, E.G.2
Blau, A.3
Dhingra, M.4
Garg, S.K.5
-
7
-
-
84871937855
-
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
-
Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175–184.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 175-184
-
-
Ratner, R.E.1
Gough, S.C.2
Mathieu, C.3
-
8
-
-
84939572199
-
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
-
Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17: 859–867.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 859-867
-
-
Ritzel, R.1
Roussel, R.2
Bolli, G.B.3
-
9
-
-
84874415108
-
LY2605541: leveraging hydrodynamic size to develop a novel basal insulin
-
Hansen RJ, Cutler GB, Vick A et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes 2012; 61(Suppl. 1): A228.
-
(2012)
Diabetes
, vol.61
, pp. A228
-
-
Hansen, R.J.1
Cutler, G.B.2
Vick, A.3
-
10
-
-
84900825441
-
Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects
-
Sinha VP, Choi SL, Soon DK et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014; 54: 792–799.
-
(2014)
J Clin Pharmacol
, vol.54
, pp. 792-799
-
-
Sinha, V.P.1
Choi, S.L.2
Soon, D.K.3
-
11
-
-
84895133323
-
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
-
Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 344–350.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 344-350
-
-
Sinha, V.P.1
Howey, D.C.2
Choi, S.L.3
Mace, K.F.4
Heise, T.5
-
12
-
-
84990219047
-
Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. Insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM)
-
(Suppl. 1A)
-
Mudaliar S, Henry RR, Ciaraldi TP et al. Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. Insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM). Diabetes 2015; 64(Suppl. 1A): LB22–LB23.
-
(2015)
Diabetes
, vol.64
, pp. LB22-LB23
-
-
Mudaliar, S.1
Henry, R.R.2
Ciaraldi, T.P.3
-
13
-
-
84906691684
-
Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects
-
Henry RR, Mudaliar S, Ciaraldi TP et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 2014; 37: 2609–2615.
-
(2014)
Diabetes Care
, vol.37
, pp. 2609-2615
-
-
Henry, R.R.1
Mudaliar, S.2
Ciaraldi, T.P.3
-
14
-
-
84990242710
-
Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial
-
May 12 [Epub ahead of print]
-
Morrow LA, Hompesch M, Jacober SJ, Choi SL, Qu Y, Sinha VP. Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial. Diabetes Obes Metab 2016; May 12 [Epub ahead of print] doi:10.1111/dom.12691.
-
(2016)
Diabetes Obes Metab
-
-
Morrow, L.A.1
Hompesch, M.2
Jacober, S.J.3
Choi, S.L.4
Qu, Y.5
Sinha, V.P.6
-
15
-
-
84893090167
-
Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism
-
Moore MC, Smith MS, Sinha VP et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014; 63: 494–504.
-
(2014)
Diabetes
, vol.63
, pp. 494-504
-
-
Moore, M.C.1
Smith, M.S.2
Sinha, V.P.3
-
16
-
-
0031851293
-
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
-
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
-
(1998)
Diabet Med
, vol.15
, pp. 539-553
-
-
Alberti, K.G.1
Zimmet, P.Z.2
-
17
-
-
84874413470
-
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study
-
Rosenstock J, Bergenstal RM, Blevins TC et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013; 36: 522–528.
-
(2013)
Diabetes Care
, vol.36
, pp. 522-528
-
-
Rosenstock, J.1
Bergenstal, R.M.2
Blevins, T.C.3
-
18
-
-
84938561571
-
Performance of an electronic diary system for intensive insulin management in Global Diabetes Clinical Trials
-
Bastyr EJ III, Zhang S, Mou J et al. Performance of an electronic diary system for intensive insulin management in Global Diabetes Clinical Trials. Diabetes Technol Ther 2015; 17: 571–579.
-
(2015)
Diabetes Technol Ther
, vol.17
, pp. 571-579
-
-
Bastyr, E.J.1
Zhang, S.2
Mou, J.3
-
19
-
-
54549114505
-
General multistage gatekeeping procedures
-
Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J 2008; 50: 667–677.
-
(2008)
Biom J
, vol.50
, pp. 667-677
-
-
Dmitrienko, A.1
Tamhane, A.C.2
Wiens, B.L.3
-
20
-
-
84921676349
-
Estimation of group means when adjusting for covariates in generalized linear models
-
Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat 2015; 14: 56–62.
-
(2015)
Pharm Stat
, vol.14
, pp. 56-62
-
-
Qu, Y.1
Luo, J.2
-
21
-
-
84990226055
-
Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
-
[Submitted Paper]
-
Davies MJ, Russel-Jones D, Selam J-L et al. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab 2016 [Submitted Paper].
-
(2016)
Diabetes Obes Metab
-
-
Davies, M.J.1
Russel-Jones, D.2
Selam, J.-L.3
-
22
-
-
84990211099
-
A Randomized Clinical Trial of Basal Insulin Peglispro versus NPH in Insulin-Naïve Patients with Type 2 Diabetes: IMAGINE 6
-
[Submitted Paper]
-
Grunberger G, Chen L, Rodríguez Á et al. A Randomized Clinical Trial of Basal Insulin Peglispro versus NPH in Insulin-Naïve Patients with Type 2 Diabetes: IMAGINE 6. Diabetes Obes Metab 2016 [Submitted Paper].
-
(2016)
Diabetes Obes Metab
-
-
Grunberger, G.1
Chen, L.2
Rodríguez, Á.3
-
23
-
-
84990202423
-
A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1
-
[Submitted Paper]
-
Garg SK, Dreyer M, Jinnouchi H et al. A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1. Diabetes Obes Metab 2016 [Submitted Paper].
-
(2016)
Diabetes Obes Metab
-
-
Garg, S.K.1
Dreyer, M.2
Jinnouchi, H.3
-
24
-
-
84962129833
-
Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with Type 2 diabetes previously treated with basal insulin: IMAGINE 5
-
Buse JB, Rodbard HW, Trescoli Serrano C et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with Type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care 2016; 39: 92–100.
-
(2016)
Diabetes Care
, vol.39
, pp. 92-100
-
-
Buse, J.B.1
Rodbard, H.W.2
Trescoli Serrano, C.3
-
25
-
-
84990179399
-
A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
-
Bergenstal RM, Lunt H, Franek E et al. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab 2016 doi: 10.1111/dom.12698.
-
(2016)
Diabetes Obes Metab
-
-
Bergenstal, R.M.1
Lunt, H.2
Franek, E.3
-
26
-
-
84868131614
-
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes
-
Bergenstal RM, Rosenstock J, Arakaki RF et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140–2147.
-
(2012)
Diabetes Care
, vol.35
, pp. 2140-2147
-
-
Bergenstal, R.M.1
Rosenstock, J.2
Arakaki, R.F.3
-
27
-
-
84990175032
-
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials
-
[Submitted Paper]
-
Ginsberg H, Cariou B, Orchard T et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials. Diabetes Obes Metab 2016 [Submitted Paper].
-
(2016)
Diabetes Obes Metab
-
-
Ginsberg, H.1
Cariou, B.2
Orchard, T.3
-
28
-
-
84858110025
-
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis
-
Chaudhuri A, Rosenstock J, DiGenio A et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev 2012; 28: 258–267.
-
(2012)
Diabetes Metab Res Rev
, vol.28
, pp. 258-267
-
-
Chaudhuri, A.1
Rosenstock, J.2
DiGenio, A.3
-
29
-
-
33748522381
-
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study
-
Gerstein HC, Yale JF, Harris SB et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med 2006; 23: 736–742.
-
(2006)
Diabet Med
, vol.23
, pp. 736-742
-
-
Gerstein, H.C.1
Yale, J.F.2
Harris, S.B.3
-
30
-
-
33244479164
-
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
-
Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442–451.
-
(2006)
Diabetologia
, vol.49
, pp. 442-451
-
-
Yki-Jarvinen, H.1
Kauppinen-Makelin, R.2
Tiikkainen, M.3
-
31
-
-
84969543105
-
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
-
Hoogwerf BJ, Lincoff AM, Rodriguez A et al. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol 2016; 15: 78.
-
(2016)
Cardiovasc Diabetol
, vol.15
, pp. 78
-
-
Hoogwerf, B.J.1
Lincoff, A.M.2
Rodriguez, A.3
-
32
-
-
18244382304
-
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
-
Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–1351.
-
(2005)
J Clin Invest
, vol.115
, pp. 1343-1351
-
-
Donnelly, K.L.1
Smith, C.I.2
Schwarzenberg, S.J.3
-
33
-
-
84921818351
-
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
-
Vatner DF, Majumdar SK, Kumashiro N et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci 2015; 112: 1143–1148.
-
(2015)
Proc Natl Acad Sci
, vol.112
, pp. 1143-1148
-
-
Vatner, D.F.1
Majumdar, S.K.2
Kumashiro, N.3
-
34
-
-
84878248928
-
Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
-
Mashhood A, Railkar R, Yokoo T et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging 2013; 37: 1359–1370.
-
(2013)
J Magn Reson Imaging
, vol.37
, pp. 1359-1370
-
-
Mashhood, A.1
Railkar, R.2
Yokoo, T.3
-
35
-
-
33947131149
-
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
-
Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E829–E835.
-
(2007)
Am J Physiol Endocrinol Metab
, vol.292
, pp. E829-E835
-
-
Juurinen, L.1
Tiikkainen, M.2
Hakkinen, A.M.3
Hakkarainen, A.4
Yki-Jarvinen, H.5
-
36
-
-
34247593406
-
Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
-
Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007; 21: 137–142.
-
(2007)
J Diabetes Complications
, vol.21
, pp. 137-142
-
-
Lingvay, I.1
Raskin, P.2
Szczepaniak, L.S.3
|